Recent

% | $
Quotes you view appear here for quick access.

Neurocrine Biosciences Inc. Message Board

doc_3377 5 posts  |  Last Activity: Aug 15, 2015 11:42 PM Member since: Feb 6, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    About the ADP study delay

    by doc_3377 Aug 14, 2015 6:44 PM
    doc_3377 doc_3377 Aug 15, 2015 11:42 PM Flag

    Haha. I will bring my wife's single hot friends!

  • Reply to

    About the ADP study delay

    by doc_3377 Aug 14, 2015 6:44 PM
    doc_3377 doc_3377 Aug 15, 2015 11:40 PM Flag

    Both are neurological conditions associated with psychotic symptoms in some cases. In theory pimavanserin should be effective in ADP - and I think it will be. That said, there is always clinical trial risk... High placebo effect, etc. that can derail a trial. So if I am acad I would not want to chance a questionable result prior to getting PDP approved. The data for PDP are so strong that the FDA didn't require a second confirmatory Phase III. That's saying something. I own a massive amount of acad because I believe in the medication and understand the market need for a drug like this. I hope it works in ADP and think it will be there's always a chance it doesn't and if it doesn't let's get that result after the drug is on the market for ODO. Not before.

  • Reply to

    About the ADP study delay

    by doc_3377 Aug 14, 2015 6:44 PM
    doc_3377 doc_3377 Aug 15, 2015 8:51 PM Flag

    I'm a he. :)

    And also a psychiatrist. We need this medication!!

  • Reply to

    About the ADP study delay

    by doc_3377 Aug 14, 2015 6:44 PM
    doc_3377 doc_3377 Aug 15, 2015 8:50 PM Flag

    Yes this is exactly what I meant!!

  • You guys realize that the delay was on purpose, right??? It was a mistake to run the study in the first place prior to approval of the PDP indication. Too much clinical risk as it would call into question the data with a poor outcome. It is simply not done and I was shocked when ACAD was pursuing it so aggressively without being on the market first. And they clearly should have been more focused on the NDA for PDP. Pimavanserin has great data, breakthrough status and doctors are waiting for novel antipsychotics. And it should be efficacious and safe in ADP. Just lets get the medication on the market first!

NBIX
46.67+0.41(+0.89%)Aug 28 4:00 PMEDT